Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Free Cash Flow (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Free Cash Flow for 4 consecutive years, with -$5.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 91.82% to -$5.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$167.0 million, a 37.4% increase, with the full-year FY2025 number at -$167.0 million, up 37.4% from a year prior.
  • Free Cash Flow was -$5.2 million for Q4 2025 at Phathom Pharmaceuticals, up from -$14.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$5.2 million in Q4 2025 to a low of -$84.9 million in Q1 2025.
  • A 4-year average of -$45.0 million and a median of -$42.4 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: plummeted 221.53% in 2024, then soared 91.82% in 2025.
  • Phathom Pharmaceuticals' Free Cash Flow stood at -$40.6 million in 2022, then fell by 9.18% to -$44.3 million in 2023, then plummeted by 43.06% to -$63.3 million in 2024, then skyrocketed by 91.82% to -$5.2 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Free Cash Flow are -$5.2 million (Q4 2025), -$14.2 million (Q3 2025), and -$62.7 million (Q2 2025).